The Readout Loud

350 Episodo

1. 287: 2023 in review, CEO report cards, and a look at the year ahead

   Publicado: 21/12/2023
2. 286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

   Publicado: 14/12/2023
3. 285: CRISPR history, biotech struggles, & a big week for deals

   Publicado: 7/12/2023
4. 284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

   Publicado: 30/11/2023
5. 283: A CRISPR milestone, algorithms amok, & biotech mixology

   Publicado: 16/11/2023
6. From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

   Publicado: 13/11/2023
7. 282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

   Publicado: 9/11/2023
8. 281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

   Publicado: 2/11/2023
9. 280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

   Publicado: 26/10/2023
10. 279: Live from the 2023 STAT Summit

    Publicado: 19/10/2023
11. 278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

    Publicado: 12/10/2023
12. 277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus

    Publicado: 5/10/2023
13. 276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump

    Publicado: 28/9/2023
14. 275: A thorny ALS debate at the FDA, and the promise of artificial wombs

    Publicado: 21/9/2023
15. 274: Covid’s latest surge, Alnylam at the FDA, & the end of an era

    Publicado: 14/9/2023
16. 273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

    Publicado: 7/9/2023
17. 272: Vivek's star turn, leaky drug data, & biotech as family business

    Publicado: 24/8/2023
18. 271: Racing for gene therapy, a pioneering approval, & startups in the lurch

    Publicado: 18/8/2023
19. 270: Your guide to Wegovy’s blockbuster heart study

    Publicado: 10/8/2023
20. 269: Biotech layoffs, eye drug drama, & gene therapy milestones

    Publicado: 3/8/2023